Molecular Subtyping of Invasive Breast Carcinoma by Immunohistochemistry and Five-Year Survival Study

  • Raja Silvan Vipparla Pathology Department, BARC Hospital
  • Raji Tejas Naidu Pathology Department, BARC Hospital
  • Susan Cherian Pathology Department, BARC Hospital
  • Suresh S Shettigar Pathology Department, BARC Hospital
Keywords: immunohistochemistry, invasive breast carcinoma, molecular subtyping

Abstract

Background: Global gene expression profiling for Invasive breast carcinoma (IBC) has identified intrinsic subtypes of IBC with differing clinical outcomes and response to therapy. As genotyping assays are limited by availability and cost, we have used Immunohistochemistry (IHC) surrogates to classify IBC into molecular subtypes. Methods: Representative tumor blocks of 158 surgical specimens of IBC between 2007 to 2017, were selected and IHC done for ER, PR, Her2, Ki67, CK 5/6 and EGFR. The cases were classified into 7 Molecular subtypes (Luminal A, Luminal B, Luminal HER2PR+, Luminal HER2PR-, HER2Enriched, Basal like (BLBC) and non classifiable (NCBC) and correlated with clinico-pathological findings. Five- year survival rate was calculated for patients diagnosed between 2007 to 2013. Result: The most common subtype was Luminal A (31.0%), followed by Luminal B (25.3%), NCBC (14.6%) and HER2 enriched (13.3%). Among post-menopausal women, common subtypes were Luminal A (33.8%) and Luminal B (24.4%). Among premenopausal women, most cases were NCBC (27.8%) and BLBC (22.2%).  61.2% of Luminal A were Grade2 and 22.4% were Grade 1. Many cases of Luminal B and HER2 positive cases were of Grade3 (45.0%) and (57.1%) respectively. Of the triple-negative category (BLBC & NCBC), 73% were Grade3 with statistically significant correlation (p value < 0.001). Most of these cases were in Tumor stage T2 (70%), followed by T1 (22.3%). Nodal metastasis was seen in 39.6% and 65% respectively of Luminal A and Luminal B subtypes. Distant metastases on follow-up were present in 15.8%, which included HER2 enriched subtype (28.5%), followed by BLBC (20.0%) and NCBC (17.4%). Luminal A cases, had better survival accounting for 88% of all survivors. Conclusion: Molecular subtyping of IBC using IHC was useful to understand the clinicopathological distinctiveness of each subtype.

References

The GLOBOCAN 2018 database, IARC Global Cancer Observatory, Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018, PRESS RELEASE N° 263, Geneva, Switzerland, 12 September 2018.

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.

Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132:1133-45.

National Cancer Registry Programme. Consolidated report of the population-based cancer registries 1990-1996. New Delhi: Indian Council of Medical Research; 2001.

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 47:1999–2009.

Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol 2014; 2014:469251.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.

Tang P, Tse GM. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. Arch Pathol Lab Med 2016; 140:806-14.

American Joint Committee on Cancer (AJCC) Cancer Staging Manual 7th ed. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III H. eds. New York: Springer. 2009.

International Union against Cancer (UICC): TNM classification of malignant tumors 7th ed. Sobin LH, Gospodarowicz MK, Wittekind Ch. Eds. Wiley-Blackwell. Oxford. 2009.

Tiwari S, Malik R, Trichal VK, Nigam RK, Rai A, Balani S et al. Breast Cancer: Correlation of Molecular Classification with Clinicohistopathology. Sch. J. App. Med. Sci 2015; 3:1018-26.

Hadizadeh, M.; Arani, H. Z.; Olya, M. Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival. Iran Red Crescent Med J 2018;20: e57931.

Kumar N, Patni P, Agarwal A, Khan MA, Parashar N. Prevalence of molecular subtypes of invasive breast cancer: A retrospective study. Med J Armed Forces India 2015; 71:254-8.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 2009; 55:346-52.

Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch 2014; 465:1-14.

Calderella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol 2013:139:617–23.

Mahajan S, Singh A, Joneja A, Kapoor S. Molecular Evaluation of Subtypes of Breast Cancer by Immunohistochemical expression of Estrogen Receptor (ER), Progesterone Receptor (PR), HER2neu, Cytokeratin 5/6 and Ki 67. International Journal of Science and Research (IJSR) 2016; 5:184-8.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11:4741-8

Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M, Massarweh S. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat 2014;148(2):437-44.

Zaha DC, Lazăr E, Lăzureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Romanian Journal of Morphology and Embryology = Revue Roumaine de Morphologie et Embryologie 2010 ;51(1):85-9.

Liao GS, Hsu HM, Chu CH, Hong ZJ, Fu C, Chou YC et al. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. J Med Sci 2018; 38: 54- 61.

Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 2017; 7:45411.

Mao JH, Diest PJV, Perez-Losada J, Snijders AM. Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. Sci Rep 2017; 7:12587.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736-50.

Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis 2015; 32:125-33.

Published
2021-09-30
Section
Original Article